{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:15:05Z","timestamp":1761516905064,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.4158\/ep-2019-0552","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T10:04:47Z","timestamp":1599127487000},"page":"818-829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Similar Cardiovascular Outcomes Between Insulin Detemir and Insulin Glargine In Type 2 Diabetic Patients With Extremely Atherosclerotic Cardiovascular Disease Risks"],"prefix":"10.1016","volume":"26","author":[{"given":"Tien-Hsing","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Ching","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Hung","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Chung","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szu-Tah","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Hsuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Yun","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP-2019-0552_bb0010","first-page":"229","volume":"339","author":"Haffner","year":"1998","journal-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction"},{"key":"10.4158\/EP-2019-0552_bb0015","first-page":"2215","volume":"375","author":"Sarwar","year":"2010","journal-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies"},{"key":"10.4158\/EP-2019-0552_bb0020","first-page":"1728","volume":"119","author":"Preis","year":"2009","journal-title":"Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005"},{"key":"10.4158\/EP-2019-0552_bb0025","first-page":"1371","volume":"90","author":"Boccara","year":"2004","journal-title":"Interplay of diabetes and coronary heart disease on cardiovascular mortality"},{"key":"10.4158\/EP-2019-0552_bb0030","first-page":"1961","volume":"24","author":"Shou","year":"2015","journal-title":"Diabetes is an independent risk factor for stroke recurrence in stroke patients: a meta-analysis"},{"issue":"suppl 2","key":"10.4158\/EP-2019-0552_bb0035","first-page":"S14","volume":"44","author":"Morrish","year":"2001","journal-title":"Mortality and causes of death in the WHO multinational study of vascular disease in diabetes"},{"key":"10.4158\/EP-2019-0552_bb0040","first-page":"837","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group.","year":"1998","journal-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)"},{"key":"10.4158\/EP-2019-0552_bb0045","first-page":"2545","volume":"358","author":"Gerstein","year":"2008","journal-title":"Effects of intensive glucose lowering in type 2 diabetes"},{"key":"10.4158\/EP-2019-0552_bb0050","first-page":"2560","volume":"358","author":"Patel","year":"2008","journal-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes"},{"key":"10.4158\/EP-2019-0552_bb0055","first-page":"818","volume":"364","author":"Gerstein","year":"2011","journal-title":"Long-term effects of intensive glucose lowering on cardiovascular outcomes"},{"key":"10.4158\/EP-2019-0552_bb0060","first-page":"145","volume":"369","author":"Wing","year":"2013","journal-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes"},{"key":"10.4158\/EP-2019-0552_bb0065","first-page":"923","volume":"132","author":"Cavender","year":"2015","journal-title":"Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the reduction of atherothrombosis for continued health (REACH) registry"},{"journal-title":"Guidance for industry: diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes","year":"2008","author":"Food and Drug Administration, HHS.","key":"10.4158\/EP-2019-0552_bb0070"},{"issue":"suppl 1","key":"10.4158\/EP-2019-0552_bb0075","first-page":"S73","volume":"41","year":"2018","journal-title":"8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018"},{"key":"10.4158\/EP-2019-0552_bb0080","first-page":"319","volume":"367","author":"Gerstein","year":"2012","journal-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia"},{"key":"10.4158\/EP-2019-0552_bb0085","first-page":"254","volume":"114","author":"Hsieh","year":"2015","journal-title":"Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database"},{"key":"10.4158\/EP-2019-0552_bb0090","first-page":"224","volume":"232","author":"Chang","year":"2014","journal-title":"Continuation of statin therapy and a decreased risk of atrial fibrillation\/flutter in patients with and without chronic kidney disease"},{"key":"10.4158\/EP-2019-0552_bb0095","first-page":"500","volume":"24","author":"Cheng","year":"2014","journal-title":"Validation of acute myocardial infarction cases in the national health insurance research database in taiwan"},{"key":"10.4158\/EP-2019-0552_bb0100","first-page":"236","volume":"20","author":"Cheng","year":"2011","journal-title":"Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan"},{"key":"10.4158\/EP-2019-0552_bb0105","first-page":"157","volume":"104","author":"Lin","year":"2005","journal-title":"Accuracy of diabetes diagnosis in health insurance claims data in Taiwan"},{"key":"10.4158\/EP-2019-0552_bb0110","first-page":"961","volume":"137","author":"Hicks","year":"2018","journal-title":"2017 Cardiovascular and stroke endpoint definitions for clinical trials"},{"key":"10.4158\/EP-2019-0552_bb0115","first-page":"1906","volume":"308","author":"Wu","year":"2012","journal-title":"Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection"},{"key":"10.4158\/EP-2019-0552_bb0120","first-page":"1092","volume":"172","author":"Austin","year":"2010","journal-title":"Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score"},{"key":"10.4158\/EP-2019-0552_bb0125","first-page":"69","volume":"25","author":"Garber","year":"2019","journal-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2019 executive summary"},{"key":"10.4158\/EP-2019-0552_bb0130","first-page":"723","volume":"377","author":"Marso","year":"2017","journal-title":"Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes"},{"key":"10.4158\/EP-2019-0552_bb0135","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2337\/dc10-0666","volume":"33","author":"Giovannucci","year":"2010","journal-title":"Diabetes and cancer: a consensus report"},{"key":"10.4158\/EP-2019-0552_bb0140","first-page":"73","volume":"116","author":"Mayer","year":"2010","journal-title":"Treatment with insulin glargine (lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells"},{"key":"10.4158\/EP-2019-0552_bb0145","first-page":"1743","volume":"374","author":"Hemkens","year":"2009","journal-title":"Insulin glargine and cancer"},{"key":"10.4158\/EP-2019-0552_bb0150","first-page":"3647","volume":"35","author":"Wu","year":"2017","journal-title":"Long-term use of long-acting insulin analogs and breast cancer incidence in women with type 2 diabetes"},{"key":"10.4158\/EP-2019-0552_bb0155","first-page":"613","volume":"364","author":"Pauwels","year":"2004","journal-title":"Burden and clinical features of chronic obstructive pulmonary disease (COPD)"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20481650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20481650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:09:03Z","timestamp":1761516543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20481650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1530891X20481650"],"URL":"https:\/\/doi.org\/10.4158\/ep-2019-0552","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Similar Cardiovascular Outcomes Between Insulin Detemir and Insulin Glargine In Type 2 Diabetic Patients With Extremely Atherosclerotic Cardiovascular Disease Risks","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP-2019-0552","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}